BioNTech announced that its Phase 2/3 trial of mRNA cancer immunotherapy BNT113 combined with pembrolizumab did not meet the first primary endpoint of progression-free survival in treating HPV16-positive head and neck cancer. However, the trial will continue to evaluate the second primary endpoint, overall survival, which could still demonstrate a significant benefit. This ongoing assessment is crucial as mRNA therapies aim to provide durable immune responses and potentially extend patient survival. The results highlight the need for new HPV-targeted treatments, as current options remain limited.
BioNTech’s update on its cancer immunotherapy trial comes as the company’s ADR trades at USD 93.03 on Pluang, down 2.93% as of Oct 13, 2026, 18:02 WIB. The stock’s market cap stands at $24.08 billion, reflecting ongoing investor interest despite trial challenges. The 52-week trading range shows a high of $119.34 and a low of $83.89, indicating notable price volatility over the past year.
